Navigation Links
Blocking key enzyme in cancer cells could lead to new therapy
Date:8/1/2013

Researchers from the University of Illinois at Chicago College of Medicine have identified a characteristic unique to cancer cells in an animal model of cancer -- and they believe it could be exploited as a target to develop new treatment strategies.

An enzyme that metabolizes the glucose needed for tumor growth is found in high concentrations in cancer cells, but in very few normal adult tissues. Deleting the gene for the enzyme stopped the growth of cancer in laboratory mice, with no associated adverse effects, reports Nissim Hay, UIC professor of biochemistry and molecular genetics, and his colleagues in the August 12 issue of Cancer Cell.

Targeting glucose metabolism for cancer therapy -- while avoiding adverse effects in other parts of the body -- has been a "questionable" strategy, Hay said. But he and his coworkers showed that the glucose-metabolism enzyme hexokinase-2 can be almost completely eliminated in adult mice without affecting normal metabolic functions or lifespan.

Hexokinase-2 is abundant in embryos but absent in most adult cells, where related enzymes take over its role in metabolism. One of the changes that mark a cell as cancerous is expression of the embryonic enzyme. Hay and his colleagues showed that the embryonic version is required for cancer cells to proliferate and grow, and that eliminating it halts tumor growth.

They developed a mouse strain in which they could silence or delete the HK2 gene in the adult animal, and they found that these mice could not develop or sustain lung or breast cancer tumors but were otherwise normal and healthy.

"We have deleted the HK2 gene systemically in these mice, and they have been living for more than two years now. Their lifespan is the same as normal mice," Hay said.

The researchers also looked at human lung and breast cancer cells in the lab, and found that if they eliminated all HK2, the cells stopped growing.

"We think that the process we used to delete the HK2 gene is not absolutely perfect, so there must be some low levels of HK2 in the mice. But that seems to be enough for the cells that use HK2, and the therapeutic effects on tumors in these mice are stable."

Hay thinks the enzyme is involved in making the building-blocks for the DNA of cancer cells, which need lots of all cellular components as they rapidly divide. "Without HK2, the cancer cells don't make enough DNA for new cells, and so tumor growth comes to a standstill," said Hay.


'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Mount Sinai Researchers Find that Blocking Sugar Intake May Reduce Cancer Risk or Progression in Obese and Diabetic People
2. Study shows additional role for abiraterone in blocking tumor growth in CRPC
3. Autism Speaks trailblazer study -- Blocking cell distress signals can ease autism symptoms
4. Evidence supports blocking immune response to enhance viral therapy against solid tumors
5. Researchers prevent cancer spread by blocking tissue scarring
6. Spread of Cancer May be Reduced by Maximizing Melatonin by Blocking Blue Light Says Photonic Developments LLC
7. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
8. Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
9. Targeting errant immune system enzyme kills myelodysplastic cells
10. Molecular imaging enlists prostate enzyme to detect metastases
11. DNA-altering enzyme is essential for blood cell development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR ... Medical has introduced an innovative workstation designed to reduce nursing fatigue while enhancing ... Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... (ISTS) brings its educational assistance management solution to the exhibit floor for the ... in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will serve more than ... the U.S. Soccer Foundation announced today that they have awarded nine grants to ... the Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Officer, George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing 100 North ... those who have made notable contributions to the staffing industry over the last ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... MISSISSAUGA, Ontario , Feb. 16, 2017  Aralez ... a global specialty pharmaceutical company, today announced that executive ... Healthcare Conference to be held February 22-23, 2017. ... overview of the Company at 1:35 p.m. local time ... webcast and audio archive for the event may be ...
Breaking Medicine Technology: